ESMO 2026 day one: HER2-targeted agents dominate floor talk
Start here
This page follows news from the first day of the ESMO 2026 congress, held 26 October, as reported in a daily floor digest. Coverage centered on antibody-drug conjugates and targeted therapies in breast and other solid tumors. The most-discussed items were tucatinib, the ARTEMIS-011 trial, the MOIO and SANOVO studies, and TROFUSE-005. Sacituzumab, HER2-targeting agents generally, and rezetecan also drew attention. The digest reflects what generated the most floor traffic and discussion on the day; what these trials and agents showed in detail, and how results are being received, is still unfolding as the congress continues.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- cba-usa.newsPickESMO 2026 · 26 Oct floor digest
1. tucatinib (15); 2. ARTEMIS-011 (13); 3. MOIO (13); 4. SANOVO (13); 5. TROFUSE-005 (12); 6. sacituzumab (11); 7. HER2 (10); 8. rezetecan (10)
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 27 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.